Helicobacter pylori is a gram-negative, spiral-shaped bacterium uniquely adapted to live in the acidic environment of the human stomach. Discovered in 1982, it has since been recognized as the primary cause of chronic gastritis and peptic ulcer disease, and a major risk factor for gastric cancer.

1. Global Prevalence and Risk Factors

• Over half of the world’s population carries H. pylori, with the highest rates in developing regions. Infection typically occurs in childhood and, without treatment, often persists lifelong.
• The bacterium spreads via oral–oral or fecal–oral routes—through contaminated food, water, or interpersonal contact. Crowded living conditions, poor sanitation, and lack of clean water sources significantly increase transmission risk.
• Socioeconomic status, family clustering, and certain behaviors (for example, eating food washed in untreated water) all influence one’s likelihood of acquiring the infection.

2. How the Bacterium Survives and Damages the Stomach

• H. pylori produces urease, an enzyme that converts urea into ammonia and carbon dioxide. The resulting ammonia neutralizes gastric acid around the bacterium, creating a protective “cloud” that allows it to thrive on the stomach lining.
• The bacterium’s helical shape and flagella enable it to burrow into the mucus layer overlying the gastric epithelium. Once there, it adheres to epithelial cells via specific adhesins.
• H. pylori releases toxins (notably CagA and VacA) that trigger an immune response, leading to chronic inflammation. This persistent inflammation damages the mucosal barrier, making the stomach more susceptible to acid‑induced injury.

3. Clinical Manifestations and Long‑Term Risks

• Many infected individuals remain asymptomatic. When symptoms do occur, they typically include burning or gnawing epigastric pain, often relieved by eating or antacids, bloating, early satiety, and nausea.
• Chronic infection is the leading cause of gastric and duodenal ulcers. Ulcers may present with acute pain, gastrointestinal bleeding, or perforation in severe cases.
• Long‑standing H. pylori gastritis is a well‑established risk factor for gastric adenocarcinoma and mucosa‑associated lymphoid tissue (MALT) lymphoma. Eradication therapy can reduce this cancer risk over time.

4. Diagnostic Strategies

• Non‑invasive tests include the urea breath test (measuring labeled carbon dioxide after ingestion of urea), stool antigen assay (detecting bacterial antigens in feces), and serology (detecting antibodies).
• Invasive methods—upper endoscopy with gastric biopsy—allow for histological examination, rapid urease testing, and culture. These are indicated when alarm features are present (for example, anemia, weight loss, or bleeding).
• A test-of-cure (using a urea breath or stool antigen test) is recommended at least four weeks after completing therapy to confirm eradication, especially in patients with ulcers or prior malignancy risk.

5. Effective Treatment and Prevention

• First-line eradication therapy is a 14-day course of bismuth quadruple therapy: proton‑pump inhibitor, bismuth, tetracycline, and metronidazole.
• Alternative regimens—such as rifabutin-based triple therapy or potassium‑competitive acid blocker dual therapy—are used in penicillin-allergic patients or after treatment failure.
• Preventive measures include promoting hand hygiene, safe food preparation, access to clean water, and, in some cases, screening and treating close contacts to reduce reinfection risk.
•  

Helicobacter pyloriremains a globally prevalent pathogen with significant implications for gastrointestinal health. Awareness of its transmission, clinical impact, diagnostic approaches, and treatment options is essential for both patients and providers. If you experience recurrent dyspepsia, ulcer-type pain, or have risk factors for H. pylori infection, discuss testing and management with a qualified healthcare professional to protect your long-term digestive health. Schedule your H. pylori test today at Blessono Specialist Clinic.